Keytruda takes on rare chest cancers: early trial launches
NCT ID NCT03295227
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This early-phase trial is testing the safety of the immunotherapy drug pembrolizumab (Keytruda) in 37 people with thymoma or thymic carcinoma that cannot be removed by surgery. The drug helps the immune system attack cancer cells. Researchers are looking at side effects and how well the drug controls tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda)
- What this could lead to
- If it works, this could point toward a new treatment option for people with thymoma or thymic cancer that cannot be surgically removed.
- What could go wrong
- This is a very early (Phase 1) trial with only 37 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III THYMOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.